Recent News

• 12.01.2025 - MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease
• 11.11.2025 - MannKind to Present at the Jefferies Global Healthcare Conference
• 11.10.2025 - MannKind Provides Update on Phase 3 ICoN-1 Trial of Nebulized Clofazimine for NTM Lung Disease
• 11.06.2025 - MannKind Commemorates Alfred E. Mann’s 100th Birthday with New Scholarship Program Supporting Young Adults Living with Diabetes
• 11.05.2025 - MannKind Corporation Reports Third Quarter 2025 Financial Results and Provides Business Update
• 10.29.2025 - MannKind Corporation to Hold 2025 Third Quarter Financial Results Conference Call on November 5, 2025
• 10.13.2025 - MannKind Announces U.S. FDA Accepts for Review its Supplemental Biologics License Application (sBLA) for Inhaled Insulin (Afrezza) in Children and Adolescents Aged 4-17 Years Living with Diabetes
• 10.07.2025 - MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care

Recent Filings

• 11.14.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.14.2025 - 144 Report of proposed sale of securities
• 11.12.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.10.2025 - 8-K Current report
• 11.05.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.05.2025 - 8-K Current report
• 11.05.2025 - EX-99.1 EX-99.1
• 11.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 10.09.2025 - 3 Initial statement of beneficial ownership of securities
• 10.09.2025 - 8-K Current report